Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ITF Has A Fight On Its Hands In Duchenne

Executive Summary

The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.

You may also be interested in...

Keeping Track: Cardio-Renal Drugs At Heart Of US FDA’s March Approval Binge

Seven novel agents approved in March include one accelerated approval, two rare pediatric disease priority review vouchers, two breakthrough therapy designations and one regenerative medicine advance therapy designation.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.

Sarepta Confident Of Full US Approval For Duchenne Gene Therapy By Mid-2024

Elevidys has enjoyed a strong launch, despite being restricted to a small number of Duchenne patients. Sarepta is hoping the US regulator will overlook trial problems and allow its expanded use.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts